Abivax

Abivax is a biotechnology company that focuses on the discovery, development, and commercialization of novel anti-viral therapies and vaccines. The company is based in Paris, France, and was founded in 2013. Abivax's primary product is ABX464, a first-in-class small molecule that has shown promise in clinical trials for the treatment of HIV and inflammatory diseases.

History[edit | edit source]

Abivax was founded in 2013 in Paris, France. The company was established with the goal of developing and commercializing novel anti-viral therapies and vaccines. Since its inception, Abivax has focused on the development of its primary product, ABX464.

Products[edit | edit source]

Abivax's primary product is ABX464, a first-in-class small molecule that has shown promise in clinical trials for the treatment of HIV and inflammatory diseases. ABX464 works by inhibiting the replication of the HIV virus, thereby reducing the viral load in the patient's body.

Clinical Trials[edit | edit source]

Abivax has conducted several clinical trials to test the efficacy and safety of ABX464. The results of these trials have shown that ABX464 is effective in reducing the viral load in patients with HIV and has a good safety profile.

Future Developments[edit | edit source]

Abivax continues to conduct research and development activities to further improve ABX464 and develop new anti-viral therapies and vaccines. The company is also exploring the potential of ABX464 in treating other inflammatory diseases.

See Also[edit | edit source]

Abivax Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.